OncoMatch/Clinical Trials/NCT06077760
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Is NCT06077760 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Intismeran autogene and Pembrolizumab for non-small cell lung cancer.
Treatment: Intismeran autogene · Pembrolizumab — The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage II, IIIA, IIIB (N2)
Prior therapy
Must have received: platinum-based chemotherapy — adjuvant
Has received at least one dose of adjuvant treatment with standard of care platinum doublet chemotherapy
Cannot have received: neoadjuvant therapy
Received prior neoadjuvant therapy for their current NSCLC diagnosis
Cannot have received: radiation therapy
Received or is a candidate to receive radiotherapy for their current NSCLC diagnosis
Cannot have received: anti-PD-1 therapy
Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-PD-ligand 1 (L1), or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
Cannot have received: systemic anticancer therapy
Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Oncology and Hematology ( Site 0039) · Anchorage, Alaska
- The University of Arizona Cancer Center - North Campus ( Site 0071) · Tucson, Arizona
- YUMA REGIONAL MEDICAL CENTER CANCER CENTER ( Site 0020) · Yuma, Arizona
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0059) · Los Angeles, California
- Hoag Memorial Hospital Presbyterian ( Site 4042) · Newport Beach, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify